Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorChongqing Medical University
About this trial
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).
The main question\[s\] it aims to answer are:
\[question 1\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \[question 2\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?
Eligibility criteria
Qualifiers
Total participants from NHANES 2017-2020
Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.
Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol/mol); (3) fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L (200 mg/dL).
Overweight or obesity: defined as BMI≥25 kg/m2 in Caucasians or BMI≥23 kg/m2 in Asians
Disqualifiers
Liver ultrasound data not available
participants without complete clinical data
participants under 18 years old
participants with cancer.
Trial design
Treatments tested in this trial
- high-sensitivity C-reactive protein to albumin ratio
Treatment groups
7,000 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov